SPARC

SPARC Full Name

secreted protein, acidic, cysteine-rich (osteonectin)

SPARC Introduction

SPARC (secreted protein acidic and rich in cysteine), also known as osteonectin, is a matricellular glycoprotein that has emerged as a critical regulator of cell–extracellular matrix (ECM) interactions—an area that often frustrates researchers and drug developers due to its complexity and context-dependent behavior. Structurally, SPARC contains an acidic N-terminal domain, a follistatin-like domain, and a C-terminal ECM-binding region, enabling it to directly interact with collagen and other matrix components. This positioning allows SPARC to act as a dynamic modulator rather than a static structural protein, influencing how cells sense and remodel their microenvironment. In tissues such as skin, SPARC expression is significantly higher in younger individuals, where it supports fibroblast function and maintains ECM integrity through activation of the TGF-β signaling pathway. Loss or downregulation of SPARC disrupts collagen deposition and fibronectin assembly, leading to weakened tissue architecture—an insight that directly addresses challenges in aging research, wound healing, and regenerative medicine.

Figure 1. Possible role of osteopontin (OPN) in cardiac healing and remodeling after MI.(Sources: Matsui Y, et al.; 2010)

Functionally, SPARC sits at the intersection of ECM remodeling, growth factor signaling, and cellular stress responses, making it both highly influential and difficult to target precisely. One of its defining roles is the regulation of collagen maturation and assembly, where it facilitates post-translational processing and stabilization of fibrillar collagen networks. SPARC also modulates signaling pathways such as TGF-β and interacts with enzymes like ADAMTS1 to control matrix turnover and tissue stiffness. Adding another layer of complexity, SPARC expression is tightly regulated under cellular stress conditions, including the unfolded protein response (UPR). For example, the ER stress sensor IRE1 can directly degrade SPARC mRNA via its RNase activity, reducing SPARC levels and thereby altering ECM deposition and cell–matrix signaling. This regulatory axis highlights a key pain point in translational research: SPARC activity is not only tissue-specific but also highly sensitive to intracellular stress, complicating efforts to design consistent therapeutic strategies.

Clinically, SPARC demonstrates a paradoxical, context-dependent role across multiple diseases, which both increases its therapeutic appeal and complicates its application. In cancer, SPARC can act as a tumor suppressor by inhibiting cell proliferation and tumor formation through autocrine and paracrine mechanisms, particularly observed in glioma models. However, it can simultaneously promote tumor cell migration and invasion by activating pathways such as FAK/Rho/F-actin, underscoring its dualistic nature. In cardiovascular disease, especially ischemic heart conditions, SPARC plays a balancing role in angiogenesis: while it cooperates with VEGF in vascular remodeling, it can also suppress excessive endothelial cell proliferation, preventing abnormal vessel formation. Furthermore, in cardiac fibrosis, SPARC contributes to collagen cross-linking and ECM stiffening, promoting fibrotic progression but also maintaining structural integrity of the myocardium. These seemingly contradictory roles reflect a broader challenge for researchers—SPARC is not simply "pro-" or "anti-disease," but rather a context-sensitive regulator whose function depends on tissue type, disease stage, and signaling environment. As a result, SPARC is increasingly viewed as both a biomarker and a therapeutic target, particularly in areas such as fibrosis, cancer progression, and regenerative medicine, where precise modulation of ECM dynamics is critical.

Alternate Names for SPARC

ON; BM-40; Osteonectin; Basement-membrane protein 40; Osteonectin (secreted protein, acidic, cysteine-rich); SPARC precursor; Secreted protein acidic and rich in cysteine; cysteine-rich protein;secreted protein, acidic, cysteine-rich (osteonectin); SPRC_HUMAN; SPARC [Precursor]; SPARC

• 1.Ham SM, et al.; SPARC Is Highly Expressed in Young Skin and Promotes Extracellular Matrix Integrity in Fibroblasts via the TGF-β Signaling Pathway. Int J Mol Sci. 2023, 24(15):12179.
  2.Athanasopoulos EN, et al.; Activation of Unfolded Protein Response Pathway in Malignancies: Interplay with Extracellular Matrix and Targeting Perspectives. Cancers (Basel). 2025 Jun 13;17(12):1972.
  3.Matsui Y, et al.; Role of matricellular proteins in cardiac tissue remodeling after myocardial infarction. World J Biol Chem. 2010, 1(5):69-80.